Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC

Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond to first generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFR T790M mutation....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Walter, Annette O., Sjin, Robert Tjin Tham, Haringsma, Henry J., Ohashi, Kadoaki, Sun, Jing, Lee, Kwangho, Dubrovskiy, Aleksander, Labenski, Matthew, Zhu, Zhendong, Wang, Zhigang, Sheets, Michael, Martin, Thia St, Karp, Russell, van Kalken, Dan, Chaturvedi, Prasoon, Niu, Deqiang, Nacht, Mariana, Petter, Russell C., Westlin, William, Lin, Kevin, Jaw-Tsai, Sarah, Raponi, Mitch, Dyke, Terry Van, Etter, Jeff, Weaver, Zoe, Pao, William, Singh, Juswinder, Simmons, Andrew D., Harding, Thomas C., Allen, Andrew
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4048995/
https://ncbi.nlm.nih.gov/pubmed/24065731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0314
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg